HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6- (2- methyl- 4- (2- naphthyl)- 1,2,3,4- tetrahydroisoquinolin- 7- yl)pyridazin- 3- amine

a triple monoamine reuptake inhibitor; structure in first source

Also Known As:

BMS-820836

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridazines: 11
    - 6-(2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - 6-(2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)pyridazin-3-amine: 2

Experts

1.	Bhagwagar, Zubin: 2 articles (08/2015 - 06/2014)
2.	Zheng, Ming: 2 articles (08/2015 - 06/2014)
3.	Dunlop, Boadie W: 1 article (08/2015)
4.	Hennicken, Delphine: 1 article (08/2015)
5.	Khan, Arif: 1 article (08/2015)
6.	Lane, Roger: 1 article (08/2015)
7.	Mathew, Sanjay J: 1 article (08/2015)
8.	Nelson, Craig: 1 article (08/2015)
9.	Shelton, Richard: 1 article (08/2015)
10.	Thase, Michael E: 1 article (08/2015)

Related Diseases

1.	Treatment-Resistant Depressive Disorder 08/01/2015 - "Thus, BMS-820836 was well tolerated, with no evidence of dose-dependent discontinuations due to adverse events, but it failed to demonstrate superiority to the continuation of an existing antidepressant in patients with treatment-resistant depression. " 08/01/2015 - "Two phase 2B, randomized, double-blind studies assessed the efficacy and safety of fixed or flexible dose of triple monoamine uptake inhibitor BMS-820836 in patients with treatment-resistant depression to demonstrate whether switching to BMS-820836 was superior to the continuation of standard antidepressant treatment. "
2.	Major Depressive Disorder (Major Depressive Disorders) 06/01/2014 - "BMS-820836, a novel triple monoamine reuptake inhibitor, is an experimental monotherapy for sufferers of major depressive disorder who have had an inadequate response to an existing antidepressant treatment. "

Related Drugs and Biologics

1.	Antidepressive Agents (Antidepressants)